Capricor Therapeutics (CAPR) Capital Expenditures (2012 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Capital Expenditures of $5.1 million for Q1 2026, up 471.61% year-over-year from $896007.0 in Q1 2025, and up 207.63% quarter-over-quarter from $1.7 million in Q4 2025.
Capricor Therapeutics (CAPR) Capital Expenditures (2012 - 2026) Analysis & Trends
Capricor Therapeutics' Capital Expenditures history runs 14 years deep, the most recent figure standing at $5.1 million for Q1 2026.
- In Q1 2026, Capital Expenditures rose 471.61% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $7.1 million (up 390.28% YoY), while the FY2025 annual figure was $2.9 million, up 148.91% from the prior year.
- Capital Expenditures for Q1 2026 stood at $5.1 million, up from $1.7 million in the prior quarter.
- The five-year high for Capital Expenditures was $5.1 million in Q1 2026, with the low at $9145.0 in Q3 2024.
- The 5-year median for Capital Expenditures is $488798.0 (2024), against an average of $735584.9.
- The sharpest annual moves came in 2022 and 2024: Capital Expenditures soared 1437.75% in 2022, then plunged 96.61% in 2024.
- Capricor Therapeutics' Capital Expenditures stood at $694044.0 in 2022, then decreased by 19.51% to $558604.0 in 2023, then decreased by 12.5% to $488798.0 in 2024, then surged by 240.61% to $1.7 million in 2025, then surged by 207.63% to $5.1 million in 2026.
- Business Quant data shows CAPR's Capital Expenditures at $5.1 million in Q1 2026, $1.7 million in Q4 2025, and $55843.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | 5.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.12 Mn |
| Mar 31, 2026 | 5.12 Mn |
| Dec 31, 2025 | 1.66 Mn |
| Dec 31, 2025 | 1.66 Mn |
| Sep 30, 2025 | 55,843.00 |
| Sep 30, 2025 | 55,843.00 |
| Jun 30, 2025 | 287,738.00 |
| Jun 30, 2025 | 287,738.00 |
| Mar 31, 2025 | 896,007.00 |
| Mar 31, 2025 | 896,007.00 |
| Dec 31, 2024 | 488,798.00 |
| Dec 31, 2024 | 488,798.00 |
| Sep 30, 2024 | 9,145.00 |
| Sep 30, 2024 | 9,145.00 |
| Jun 30, 2024 | 60,340.00 |
| Jun 30, 2024 | 60,340.00 |
| Mar 31, 2024 | 608,588.00 |
| Mar 31, 2024 | 608,588.00 |
| Dec 31, 2023 | 558,604.00 |
| Dec 31, 2023 | 558,604.00 |